Document is current
Any future updates will be listed below
-
Authors
Kerr, Steven
Madia, Joan E.
Nicodemo, Catia
Sheikh, Aziz
-
Funding
Funding for this research was provided by:
HDRUK
- License Information
-
More Information
Article History
Received: 15 September 2025
Accepted: 7 April 2026
First Online: 21 April 2026
Declarations
:
: The EAVE II study was approved by the relevant Research Ethics Committee and the Public Benefit and Privacy Panel for Health and Social Care. The study was conducted using de-identified routinely collected administrative health data in accordance with applicable data protection regulations.
: Not applicable.
: AS was a member of the Scottish Government Chief Medical Officer’s COVID-19 Advisory Group and is a member of its Standing Committee on Pandemics. AS was also a member of the New and Emerging Respiratory Virus Threats Advisory Group (NERVTAG) Risk Stratification Subgroup. AS was a member of AstraZeneca’s Thrombotic Thrombocytopenic Taskforce. All AS’ roles are unremunerated. All other authors declare no competing interests.
